StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Vaishali Parekh, Prabhudas Lilladher

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byVaishali Parekh, Prabhudas LilladherHorizon: NA (inferred Swing (≤2wk))18 May 2026via Business Today

Entry₹2,339.9Inferred
Target₹2,600
Total upside +11.12% (call closed)
Stop loss₹2,200-5.98% risk
Exit₹2,2001 Jun 2026, 9:35 am
Stop-loss hit-5.98%
Follow Vaishali Parekh for new calls(23% target hit, 82 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 2 active Swing calls on GLENMARKSee 113 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 10:46 am IST
2 supporting2 neutral0 opposing
Supports the BUY call (2)

Glenmark Pharmaceuticals' subsidiary, Ichnos Glenmark Innovation (IGI), has announced a new development candidate, ISB 2301. This is a first-in-class multispecific immune cells activator designed to t

NSE · Press Release·20 May · 2w ago

(opens in new tab)

Glenmark Pharmaceuticals Inc., USA has launched Vancomycin Hydrochloride for Injection USP in 500mg/vial and 1 g/vial strengths.

NSE · Press Release·18 May · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Press Release and Management Discussion & Analysis for the Fourth Quarter ended March 31, 2026.

BSE · Company Update·29 May · 2d ago

(opens in new tab)

The Board of Directors of Glenmark Pharmaceuticals Limited considered and approved audited financial results and recommended dividend.

BSE · Board Meeting·29 May · 2d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Vaishali Parekh, Prabhudas Lilladher

Every call and its outcome